<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  WARNING: BLEEDING RISK<BR>               <BR>               <BR>                  <BR>                     <BR>                        •<BR>                        BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding (5.1, 6.1).<BR>                     <BR>                        •<BR>                        Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage (4.1, 4.2).<BR>                     <BR>                        •<BR>                        Do not start BRILINTA in patients planned to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue BRILINTA at least 5 days prior to any surgery (5.1).<BR>                     <BR>                        •<BR>                        Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of BRILINTA (5.1).<BR>                     <BR>                        •<BR>                        If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events (5.5).<BR>                  <BR>                  <BR>                     WARNING: ASPIRIN DOSE AND BRILINTA EFFECTIVENESS<BR>                  <BR>                  <BR>                     <BR>                        •<BR>                        Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided. After any initial dose, use with aspirin 75-100 mg per day (5.2, 14).<BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           <BR>                               <BR>                              WARNING: BLEEDING RISK<BR>                           <BR>                        <BR>                        <BR>                           <BR>                              •<BR>                              BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding (5.1, 6.1).<BR>                           <BR>                              •<BR>                              Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage (4.1, 4.2).<BR>                           <BR>                              •<BR>                              Do not start BRILINTA in patients planned to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue BRILINTA at least 5 days prior to any surgery (5.1).<BR>                           <BR>                              •<BR>                              Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of BRILINTA (5.1).<BR>                           <BR>                              •<BR>                              If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events (5.5).<BR>                        <BR>                        <BR>                           WARNING: ASPIRIN DOSE AND BRILINTA EFFECTIVENESS<BR>                        <BR>                        <BR>                           <BR>                              •<BR>                              Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided. After any initial dose, use with aspirin 75-100 mg per day (5.2, 14).<BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>